Should I buy or sell Zynerba Pharmaceuticals stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares. View ZYNE analyst ratings or view top-rated stocks .

What is Zynerba Pharmaceuticals' stock price target for 2024?

4 brokers have issued 1 year price objectives for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next twelve months. This suggests that the stock has a possible downside of 14.6%. View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts .

How were Zynerba Pharmaceuticals' earnings last quarter?

Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02.

What ETF holds Zynerba Pharmaceuticals' stock ?

Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio.

What other stocks do shareholders of Zynerba Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA) , GW Pharmaceuticals (GWPH) , Cronos Group (CRON) , Aurora Cannabis (ACB) , NVIDIA (NVDA) , Advanced Micro Devices (AMD) , Alibaba Group (BABA) , Shopify (SHOP) and Micron Technology (MU) .

When did Zynerba Pharmaceuticals IPO?

(ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.

Who are Zynerba Pharmaceuticals' major shareholders?

Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Beryl Capital Management LLC (9.08%), Deltec Asset Management LLC (0.88%), GTS Securities LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree. View institutional ownership trends .

Zynerba Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ZYNE)

Notice: This company has been marked as potentially delisted and may not be actively trading.

Compare

Today's Range: $1.26
▼
$1.34
50-Day Range: $1.21
▼
$1.39
52-Week Range: $0.25
▼
$1.40

Volume: 862,700 shs
Average Volume: 515,333 shs
Market Capitalization: $70.12 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $1.11

Stock Analysis Analyst Forecasts Earnings Headlines Insider Trades Ownership Short Interest Social Media

Zynerba Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Hold
2.25 Rating Score
Upside/Downside: 14.6% Downside
$1.11 Price Target
Short Interest: Healthy
25.51% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$64,033 Sold Last Quarter
Proj. Earnings Growth: Growing
From ($0.84) to ($0.49) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.09 out of 5 stars

Medical Sector

933rd out of 951 stocks

Pharmaceutical Preparations Industry

431st out of 438 stocks

1.1

Analyst's Opinion

Consensus Rating
Zynerba Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 1 buy rating, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $1.11, Zynerba Pharmaceuticals has a forecasted downside of 14.6% from its current price of $1.30.
Amount of Analyst Coverage
Zynerba Pharmaceuticals has received no research coverage in the past 90 days.

3.0

Short Interest

Percentage of Shares Shorted
25.51% of the float of Zynerba Pharmaceuticals has been sold short.
Short Interest Ratio / Days to Cover
Zynerba Pharmaceuticals has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Zynerba Pharmaceuticals has recently decreased by 4.50%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Zynerba Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Zynerba Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZYNE.

0.6

News and Social Media Coverage

Search Interest
2 people have searched for ZYNE on MarketBeat in the last 30 days.
MarketBeat Follows
Only 2 people have added Zynerba Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days.

1.7

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zynerba Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $64,033.00 in company stock.
Percentage Held by Insiders
13.04% of the stock of Zynerba Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 11.23% of the stock of Zynerba Pharmaceuticals is held by institutions.

0.6

Earnings and Valuation

Earnings Growth
Earnings for Zynerba Pharmaceuticals are expected to grow in the coming year, from ($0.84) to ($0.49) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zynerba Pharmaceuticals is -1.62, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zynerba Pharmaceuticals has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

Zynerba Pharmaceuticals, Inc. operates as a clinical stage specialty pharmaceutical company. The company focuses on developing pharmaceutically produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders. It is developing Zygel, a pharmaceutically produced cannabidiol formulated as a permeation-enhanced gel for transdermal delivery. The company was formerly known as AllTranz, Inc. and changed its name to Zynerba Pharmaceuticals, Inc. in August 2014. Zynerba Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Devon, Pennsylvania.

October 31, 2023 | finance.yahoo.com

Harmony Biosciences Reports Strong Third Quarter 2023 Financial Results

October 13, 2023 | fool.com

Why Shares of Harmony Bioscience Are Falling on Friday

December 4, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

October 11, 2023 | markets.businessinsider.com

New Possibilities For Cannabinoid Treatments: Acquisition To Transform Neuropsychiatric Disorder Therapies

October 11, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES COMPLETES ACQUISITION OF ZYNERBA PHARMACEUTICALS AND EXPANDS PIPELINE

October 4, 2023 | finance.yahoo.com

Important Information for Zynerba Pharmaceuticals Stockholders to Tender Shares for the Harmony Transaction: Process and Instructions

September 29, 2023 | finance.yahoo.com

20 Countries With Highest Rate of Epilepsy

September 29, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Stockholders Reminded to Tender Shares Before 5:00 PM New York City Time, on Tuesday October 10, 2023

December 4, 2023 | DTI Trader (Ad)

All the trading advice you’ve ever received boils down to this

All the trading advice you’ve ever received boils down to one goal and one goal only: finding a reliable edge in the markets. If you can do that, grab hold of it and never let go. Because once you have that edge, and you can count on it, you never need to do anything else.

September 27, 2023 | bizjournals.com

Harmony Biosciences extends deadline for Zynerba shareholders on up to $200M deal

September 14, 2023 | finance.yahoo.com

Insider Sell: President Terri Sebree Sells 12,401 Shares of Zynerba Pharmaceuticals Inc

September 14, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Presents Positive Data from Phase 2 INSPIRE Trial in 22q11.2 Deletion Syndrome at The Society for the Study of Behavioural Phenotypes (SSBP) 25th International Research Symposium

August 16, 2023 | msn.com

HC Wainwright & Co. Downgrades Zynerba Pharmaceuticals (ZYNE)

August 15, 2023 | finance.yahoo.com

Is Zynerba Pharmaceuticals (NASDAQ:ZYNE) In A Good Position To Deliver On Growth Plans?

August 14, 2023 | marketwatch.com

Zynerba Pharmaceuticals Shares Soar on Harmony Biosciences Deal >ZYNE

August 14, 2023 | markets.businessinsider.com

Crude Oil Down 1%; Zynerba Pharmaceuticals Shares Spike Higher

August 14, 2023 | technews.tmcnet.com

ZYNE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Zynerba Pharmaceuticals, Inc. Is Fair to Shareholders

August 14, 2023 | finance.yahoo.com

HARMONY BIOSCIENCES TO ACQUIRE ZYNERBA PHARMACEUTICALS, INC.

July 25, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces New Date for Reconvened Annual Meeting

June 29, 2023 | finance.yahoo.com

Zynerba (ZYNE) Upgraded to Buy: What Does It Mean for the Stock?

June 28, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Further Adjournment of Annual Meeting

June 20, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals to Present at the H.C. Wainwright 4th Annual Neuropsychiatry Virtual Conference

June 13, 2023 | finance.yahoo.com

Zynerba Pharmaceuticals Announces Partial Adjournment of Annual Meeting

May 17, 2023 | bizjournals.com

Main Line CBD drug developer plans reverse stock split to boost share price

May 15, 2023 | finanznachrichten.de

Zynerba Pharmaceuticals, Inc.: Zynerba Pharmaceuticals Reports First Quarter 2023 Financial Results and Operational Highlights

May 15, 2023 | investing.com

Zynerba Pharma (ZYNE) Earnings Dates & Reports

May 15, 2023 | msn.com

Zynerba Pharmaceuticals R&D Expenses For Q1 Reach $7.1M, Here Are The Details

See More Headlines

Receive ZYNE Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zynerba Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 5/15/2023
Today: 12/04/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:ZYNE
CUSIP: N/A
CIK: 1621443
Web: www.zynerba.com
Phone: (484) 581-7505
Fax: N/A
Employees: 25
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $1.11
High Stock Price Target: $1.11
Low Stock Price Target: $1.11
Potential Upside/Downside: -14.6%
Consensus Rating: Hold
Rating Score (0-4): 2.25
Research Coverage: 4 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($0.80)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-35,040,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -90.03%
Return on Assets: -72.62%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 3.43
Quick Ratio: 3.43

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.01 per share
Price / Book: 1.29

Miscellaneous

Outstanding Shares: 53,939,000
Free Float: 46,905,000
Market Cap: $70.12 million
Optionable: Optionable
Beta: 1.32

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

Mr. Armando Anido MBA (Age 65)
Chairman & CEO
Comp: $934.53k
Ms. Terri B. Sebree (Age 65)
Pres
Comp: $729.15k
Mr. James E. Fickenscher (Age 59)
CFO & VP of Corp. Devel. (Leave of Absence)
Comp: $607.62k
Mr. Kenneth T. Jones (Age 59)
VP, Corp. Controller & Interim CFO
Mr. Albert P. Parker II (Age 57)
Chief Legal Officer & Corp. Sec.
Mr. Joseph Apostolico
VP of HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZYNE Stock Analysis - Frequently Asked Questions

Should I buy or sell Zynerba Pharmaceuticals stock right now?: 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zynerba Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" ZYNE shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ZYNE, but not buy additional shares or sell existing shares.
View ZYNE analyst ratings or view top-rated stocks.
What is Zynerba Pharmaceuticals' stock price target for 2024?: 4 brokers have issued 1 year price objectives for Zynerba Pharmaceuticals' shares. Their ZYNE share price targets range from $1.11 to $1.11. On average, they expect the company's share price to reach $1.11 in the next twelve months. This suggests that the stock has a possible downside of 14.6%.
View analysts price targets for ZYNE or view top-rated stocks among Wall Street analysts.
How were Zynerba Pharmaceuticals' earnings last quarter?: Zynerba Pharmaceuticals, Inc. (NASDAQ:ZYNE) posted its earnings results on Monday, May, 15th. The company reported ($0.21) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by $0.02.
What ETF holds Zynerba Pharmaceuticals' stock ?: Amplify Seymour Cannabis ETF holds 220,858 shares of ZYNE stock, representing 0.30% of its portfolio.

What other stocks do shareholders of Zynerba Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zynerba Pharmaceuticals investors own include Cara Therapeutics (CARA), GW Pharmaceuticals (GWPH), Cronos Group (CRON), Aurora Cannabis (ACB), NVIDIA (NVDA), Advanced Micro Devices (AMD), Alibaba Group (BABA), Shopify (SHOP) and Micron Technology (MU).
When did Zynerba Pharmaceuticals IPO?: (ZYNE) raised $42 million in an initial public offering on Wednesday, August 5th 2015. The company issued 3,000,000 shares at $13.00-$15.00 per share. Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity and Oppenheimer & Co. were co-managers.
Who are Zynerba Pharmaceuticals' major shareholders?: Zynerba Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Beryl Capital Management LLC (9.08%), Deltec Asset Management LLC (0.88%), GTS Securities LLC (0.22%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Armando Anido, Brian Rosenberger, Daniel L Kisner, James E Fickenscher, Kenneth T Jones, Pamela Stephenson and Terri B Sebree.
View institutional ownership trends.

This page (NASDAQ:ZYNE) was last updated on 12/4/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zynerba Pharmaceuticals Stock Price, News & Analysis (NASDAQ:ZYNE)

Zynerba Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zynerba Pharmaceuticals Stock (NASDAQ:ZYNE)

ZYNE Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ZYNE Stock Analysis - Frequently Asked Questions

Overall MarketRank^™